Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, ...

Extraordinary General Meeting of Helix Shareholders Scheduled for August 4, 2025 SOUTH SAN FRANCISCO & BOSTON, July 11, 2025 (GLOBE NEWSWIRE) -- Helix Acquisition Corp. II (“Helix”) (Nasdaq: HLXB), a ...

The securities described above are being offered pursuant to an automatic shelf registration statement on Form S-3ASR (File No. 333-269707), which was filed with the Securities and Exchange Commission ...

A new drug targets RAS-PI3Kα pathways without harmful side effects. It was developed using high-performance computing and AI.

The firm hopes that ETX-636's dual mechanism inhibiting mutant PI3Kα will give it an edge over competing products on the market.

Issued on behalf of Oncolytics Biotech Inc. "Pelareorep's clinical data across multiple tumors is striking and represents the potential for a true backbone immunotherapy to address many in-need ...

The publication, titled “ BBO-10203 inhibits tumor growth without inducing hyperglycemia by blocking RAS-PI3Kα interaction ” was published in the peer-reviewed journal Science.

After Eli Lilly snapped up Scorpion Therapeutics' PI3Kα program earlier this year, the biotech is selling off its other two clinical assets and spinning out a new company to advance its three ...

Relay Therapeutics announced updated interim clinical data for RLY-2608, an investigational inhibitor of PI3Kα designed for patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer.

Dr. Sarah Sammons discusses side effects associated with RLY-2608, and how it effects patients with HR-positive, HER2-negative advanced breast cancer. Investigators evaluated the updated efficacy of ...

The frequency of high blood glucose among patients receiving PI3K/Akt inhibitors to treat breast cancer has some oncologists wary about using the drugs at all.

Ensem Therapeutics Inc. has gained IND clearance from the FDA for ETX-636, a novel allosteric pan-mutant-selective PI3Kα inhibitor and degrader. A first-in-human trial will begin this quarter. The ...